北方药学
北方藥學
북방약학
JOURNAL OF NORTH PHARMACY
2015年
5期
131-132
,共2页
不同剂量%丙种球蛋白%川崎病
不同劑量%丙種毬蛋白%川崎病
불동제량%병충구단백%천기병
Different dosage%Intravenous immune globulin%Kawasaki disease
目的：分析不同剂量丙种球蛋白（IVIG）在川崎病（KD）临床治疗中的应用价值。方法：回顾性分析2012年1月～2014年1月我院儿科收治确诊为川崎病48例患儿的临床资料，根据IVIG治疗剂量进行分组，给予IVIG 1g/kg剂量治疗24例为观察组，给予IVIG 2g/kg剂量治疗24例为对照组，观察比较两组治疗效果及随访患儿冠脉病变（CAL）影响。结果：观察组平均黏膜充血时间少于对照组，差异具有统计学意义（P<0.05），而两组患儿热退、手足肿胀消退、淋巴结肿大消退时间比较均无显著差异（P>0.05）；观察组CAL发生率虽然略高于对照组，但差异无统计学意义（P>0.05）。结论：1g/kg剂量IVIG治疗川崎病不仅能达到常规2g/kg剂量的治疗及降低患儿CAL发生率的效果，而且相对经济、安全，值得临床推广。
目的：分析不同劑量丙種毬蛋白（IVIG）在川崎病（KD）臨床治療中的應用價值。方法：迴顧性分析2012年1月～2014年1月我院兒科收治確診為川崎病48例患兒的臨床資料，根據IVIG治療劑量進行分組，給予IVIG 1g/kg劑量治療24例為觀察組，給予IVIG 2g/kg劑量治療24例為對照組，觀察比較兩組治療效果及隨訪患兒冠脈病變（CAL）影響。結果：觀察組平均黏膜充血時間少于對照組，差異具有統計學意義（P<0.05），而兩組患兒熱退、手足腫脹消退、淋巴結腫大消退時間比較均無顯著差異（P>0.05）；觀察組CAL髮生率雖然略高于對照組，但差異無統計學意義（P>0.05）。結論：1g/kg劑量IVIG治療川崎病不僅能達到常規2g/kg劑量的治療及降低患兒CAL髮生率的效果，而且相對經濟、安全，值得臨床推廣。
목적：분석불동제량병충구단백（IVIG）재천기병（KD）림상치료중적응용개치。방법：회고성분석2012년1월～2014년1월아원인과수치학진위천기병48례환인적림상자료，근거IVIG치료제량진행분조，급여IVIG 1g/kg제량치료24례위관찰조，급여IVIG 2g/kg제량치료24례위대조조，관찰비교량조치료효과급수방환인관맥병변（CAL）영향。결과：관찰조평균점막충혈시간소우대조조，차이구유통계학의의（P<0.05），이량조환인열퇴、수족종창소퇴、림파결종대소퇴시간비교균무현저차이（P>0.05）；관찰조CAL발생솔수연략고우대조조，단차이무통계학의의（P>0.05）。결론：1g/kg제량IVIG치료천기병불부능체도상규2g/kg제량적치료급강저환인CAL발생솔적효과，이차상대경제、안전，치득림상추엄。
Objective:To analysis and research the therapeutic value of different dosage of intravenous immune globulin (IVIG) to treat Kawasaki disease (KD). Methods:According to received different IVIG treatment dosage , the treated 48 cases of Kawasaki disease patients in January 2012-January 2014 were chosed, randomly divided into two groups, each of 24 cases. Grouping measures:Observation group were treated with 1g/kg of IVIG in intravenous injection while control group were treated with 2g/kg of IVIG in intravenous injection. Comparing the the differences of therapeutic effect and its influence on coronary artery lesion (CAL) of two groups after the treatment. Result:The pyretolysis time, regression time of hand and foot swelling, and regression time of cervical lymph node of two groups showed no significant difference (P>0.05), while regression time of mucosa hyperemia of observation group was less than that of control group (P<0.05);compared with control group, CAL incidence of observation group was slightly higher, but the difference was not statistically significant(P>0.05). Conclusion:In the treatment of Kawasaki disease , IVIG(1g/kg) is not only able to achieve same therapeutic and reducing the incidence of CAL effect compared with IVIG 2g/kg , but also comparatively economical, safe, which is worthy of promotion.
